MedTrace Logo

Endovascular Denervation for the Treatment of Type 2 Diabetes Mellitus

NCT05631561 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-04-09

No results posted yet for this study

Summary

This is a prospective, multicenter, single group feasibility clinical trial to evaluate the safety and efficacy of Endovascular denervation for the treatment of type 2 diabetes mellitus (T2DM) using the Endovascular denervation system (Generator and Catheter).

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Interventions

DEVICE

Endovascular denervation System (Generator and Catheter )

All patients receive endovascular denervation (EDN) treatment

Sponsors & Collaborators

  • Shanghai Golden Leaf MedTec Co. Ltd

    lead INDUSTRY

Principal Investigators

  • Gao-Jun Teng, MD · Zhongda Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-27
Primary Completion
2024-04-01
Completion
2025-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05631561 on ClinicalTrials.gov